Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mediwound Ltd Ord Sh (NQ: MDWD )

16.68 -0.53 (-3.08%)
Streaming Delayed Price Updated: 3:56 PM EDT, Oct 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 30,117
Open 16.98
Bid (Size) 16.67 (6)
Ask (Size) 16.81 (12)
Prev. Close 17.21
Today's Range 16.55 - 17.21
52wk Range 7.450 - 24.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
From MediWound Ltd.
Via GlobeNewswire

Performance

YTD
+48.27%
+48.27%
1 Month
-4.79%
-4.79%
3 Month
-15.11%
-15.11%
6 Month
+1.65%
+1.65%
1 Year
+115.36%
+115.36%

More News

Read More
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
From MediWound Ltd.
Via GlobeNewswire
Preview: MediWound's Earnings
Via Benzinga
MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Second Quarter 2024 Financial Results
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces $25 Million Strategic Private Placement Financing
From MediWound Ltd.
Via GlobeNewswire
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
US Stocks Mixed; Jobs Figures Top Estimates For June
Via Benzinga
Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Via Benzinga
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report First Quarter 2024 Financial Results
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
Earnings Scheduled For March 21, 2024
Via Benzinga
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
From MediWound Ltd.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.